Bladder Endothelin-1 Receptor Binding of Bosentan and Ambrisentan

DOI Web Site Web Site PubMed 参考文献27件
  • Osano Ayaka
    Department of Pharmacokinetics and Pharmacodynamics, School of Pharmaceutical Sciences, University of Shizuoka, Japan
  • Yokoyama Yoshinari
    Clinical Pharmacology and Genetics, School of Pharmaceutical Sciences, University of Shizuoka, Japan
  • Hayashi Hideki
    Clinical Pharmacology and Genetics, School of Pharmaceutical Sciences, University of Shizuoka, Japan
  • Itoh Kunihiko
    Clinical Pharmacology and Genetics, School of Pharmaceutical Sciences, University of Shizuoka, Japan
  • Okura Takashi
    Laboratory of Drug Disposition & Pharmacokinetics, Faculty of PharmaScience, Teikyo University, Japan
  • Deguchi Yoshiharu
    Laboratory of Drug Disposition & Pharmacokinetics, Faculty of PharmaScience, Teikyo University, Japan
  • Ito Yoshihiko
    Department of Pharmacokinetics and Pharmacodynamics, School of Pharmaceutical Sciences, University of Shizuoka, Japan
  • Yamada Shizuo
    Department of Pharmacokinetics and Pharmacodynamics, School of Pharmaceutical Sciences, University of Shizuoka, Japan

この論文をさがす

抄録

The present study aimed to characterize bladder endothelin-1 (ET-1) receptor binding of clinically used ET-1 receptor antagonists by using [125I]ET-1. The inhibition of specific [125I]ET-1 binding was measured in the presence of ET-1 and its receptor antagonists. Specific binding of [125I]ET-1 in rat bladder was saturable and of high affinity, which characterized selective labeling of bladder ET-1 receptors. ET-1, bosentan, ambrisentan, and CI-1020 inhibited specific [125I]ET-1 binding in a concentration-dependent manner at nanomolar ranges of IC50. Nonlinear least squares regression analysis revealed the presence of high- and low-affinity ET-1 receptor sites for ambrisentan and CI-1020. Bosentan and ambrisentan significantly increased the dissociation constant for bladder [125I]ET-1 binding without affecting maximal number of binding sites (Bmax). Thus, bosentan and ambrisentan seem to bind to bladder ET-1 receptor in a competitive and reversible manner. Oral administration of bosentan caused a dose-dependent decrease in Bmax for bladder [125I]ET-1 binding, suggesting significant binding of bladder ET-1 receptors in vivo. A significant amount of pharmacologically relevant ET-1 receptors may exist in the bladder. These receptors may be implicated in the pathogenesis of lower urinary tract symptoms and may also be promising targets for the development of therapeutic agents.

収録刊行物

参考文献 (27)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ